Premium
Nude mouse model to study passive humoral immunotherapy directed against B16 F10 murine melanoma
Author(s) -
Shrayer David,
Bogaars Hendrix,
Gersten Douglas,
Hearing Vincent,
Maizel Abby,
Wanebo Harold
Publication year - 1994
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.2930570114
Subject(s) - melanoma , antibody dependent cell mediated cytotoxicity , immune system , adjuvant , antibody , immunotherapy , antigen , medicine , immunology , monoclonal antibody , in vivo , cancer research , biology , microbiology and biotechnology
A model to study passive humoral immunotherapy of experimental melanoma was generated by subcutaneous injection of B16 F10 murine melanoma cells in the midtail of BALB/C nude (nu/nu) mice. Mice were challenged with melanoma cells pretreated: (1) with complete culture medium, (2) with 10% adjuvant control serum, (3) with 10% anti‐fECA (formalinized extracellular antigens) immune serum, or (4) with a monoclonal antibody (mAb H2‐3‐3) specific for the B700 melanoma‐associated antigen. All control mice challenged with melanoma cells pretreated either with culture medium or with medium containing adjuvant control serum (Groups I and II) died during the observation period of 84 days. At day 84, 60% of the mice challenged with melanoma cells pretreated with anti‐fECA immune serum (Group III) survived, as did 100% of the mice challenged with cells pretreated with mAb H2‐3‐3 (Group IV). Injection of melanoma cells pretreated with mAb H2‐3‐3 was associated with the greatest reduction of subsequent local tumor growth and the lowest number of metastatic lung tumors. The inhibitory effects of immune sera in vivo also correlated with in vitro effects of anti‐fECA immune serum and mAb H2‐3‐3, determined on B16 F10 melanoma target cells using assays for DNA synthesis and antibody dependant cellular cytotoxicity (ADCC). In sum, this nude mouse model for the study of passive humoral immunotherapy of experimental melanoma was utilized to demonstrate significant protective effects against B16 F10 melanoma cell challenge by treatment with anti‐fECA immune sera or a melanoma‐specific monoclonal antibody. © 1994 Wiley‐Liss, Inc.